Prevalence and outcome of diuretic resistance in heart failure.
Aged
Analysis of Variance
Chi-Square Distribution
Drug Resistance
/ physiology
Female
Furosemide
/ metabolism
Heart Failure
/ drug therapy
Humans
Logistic Models
Male
Middle Aged
Prevalence
Prognosis
Registries
/ statistics & numerical data
Retrospective Studies
Sodium Potassium Chloride Symporter Inhibitors
/ metabolism
Spain
Diuretics
Furosemide
Heart failure
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
25
09
2018
accepted:
27
12
2018
pubmed:
6
1
2019
medline:
11
2
2020
entrez:
6
1
2019
Statut:
ppublish
Résumé
Diuretic resistance (DR) is common in patients with decompensated heart failure (HF), and is associated with adverse outcomes. To determine the prevalence of DR and its impact on survival among patients with decompensated HF, we prospectively evaluated the prevalence and influence on prognosis of DR (defined as persistent congestion despite ≥ 80 mg of furosemide per day) in a cohort of elderly patients from the Spanish HF registry (RICA) admitted for an acute decompensation of HF. Patients with new-onset HF were excluded. From the global cohort of 2067 patients, 435 (21%; 95% CI 19.3%-22.7%) patients met criteria for DR. Patients with DR had more comorbidities (hypercholesterolemia, diabetes mellitus, valvular disease, chronic kidney disease, and cancer) and a worse functional status compared to patients without DR. In addition, patients with DR had a higher proportion of ischemic etiology, more advanced functional class and lower left ventricular ejection fraction values. After 1 year of follow-up, all-cause mortality was higher in patients with DR with an adjusted hazard ratio of 1.37 (95% CI 1.06-1.79; p = 0.018). The prevalence of DR in a cohort of elderly patients admitted for acute HF decompensation is 21%. DR is an independent predictor of 1-year mortality.
Identifiants
pubmed: 30610440
doi: 10.1007/s11739-018-02019-7
pii: 10.1007/s11739-018-02019-7
doi:
Substances chimiques
Sodium Potassium Chloride Symporter Inhibitors
0
Furosemide
7LXU5N7ZO5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
529-537Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Références
JAMA Cardiol. 2017 Sep 1;2(9):950-958
pubmed: 28700781
N Engl J Med. 2011 Mar 3;364(9):797-805
pubmed: 21366472
Int J Cardiol. 2018 May 1;258:185-191
pubmed: 29544928
Cardiology. 2009;113(1):12-9
pubmed: 18931492
Nat Rev Cardiol. 2015 Mar;12(3):184-92
pubmed: 25560378
Postgrad Med J. 2003 May;79(931):268-71
pubmed: 12782772
N Engl J Med. 2018 Feb 15;378(7):684-685
pubmed: 29443667
Circ Heart Fail. 2009 Jan;2(1):56-62
pubmed: 19750134
Ann Intern Med. 2017 Nov 21;167(10):698-705
pubmed: 28973663
Eur J Intern Med. 2014 Jan;25(1):67-72
pubmed: 24070521
Postgrad Med J. 2016 May;92(1087):260-6
pubmed: 26739849
QJM. 2014 Dec;107(12):989-94
pubmed: 24947341
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
J Cardiovasc Pharmacol. 1997 Mar;29(3):367-72
pubmed: 9125675
Circ Heart Fail. 2014 Mar 1;7(2):261-70
pubmed: 24379278
Eur J Heart Fail. 2017 Aug;19(8):1014-1022
pubmed: 28105769
Am Heart J. 2005 Feb;149(2):209-16
pubmed: 15846257
J Card Fail. 2016 Jul;22(7):529-36
pubmed: 26576715
Int J Cardiol. 2014 Mar 1;172(1):127-31
pubmed: 24452223
Eur Heart J. 2014 May 14;35(19):1284-93
pubmed: 24585267
J Card Fail. 2014 Jun;20(6):392-9
pubmed: 24704538
Am Heart J. 2002 Jul;144(1):31-8
pubmed: 12094185
Eur J Heart Fail. 2014 Nov;16(11):1230-40
pubmed: 25287144